嗜酸粒细胞水平对急性加重期慢性阻塞性肺疾病患者治疗效果与生存状况的影响
|
摘要
目的探究嗜酸粒细胞水平对急性加重期慢性阻塞性肺疾病患者治疗效果与生存状况的影响。方法回顾性分析2015年12月至2017年12月本院收治的148例急性加重期慢性阻塞性肺疾病患者为研究对象,依据患者嗜酸粒细胞水平将其分为低嗜酸粒细胞水平组(Eos≤2%)和高嗜酸粒细胞水平组(Eos>2%),统计两组患者的临床资料及各项指标,比较两组患者的治疗效果及生存状况的差异。结果高嗜酸粒细胞水平组患者相较于低嗜酸粒细胞水平组患者住院时间更短、死亡率更低,差异具有统计学意义(P<0.05);高嗜酸粒细胞水平组患者治疗总有效率为93.94%,低嗜酸粒细胞水平组患者治疗总有效率为78.05%,差异具有统计学意义(P<0.05);高嗜酸粒细胞水平组患者并发症发生率为12.12%,低嗜酸粒细胞水平组患者并发症发生率为21.96%,差异具有统计学意义(P<0.05)。结论高嗜酸粒细胞水平的急性加重期慢性阻塞性肺疾病患者对激素治疗有更好的反应,能够缩短患者住院时间,降低患者并发症发生率及死亡率,改善患者生存状况。
Objective To investigate the effect of eosinophils on the treatment and survival of patients with chronic obstructive pulmonary disease during acute exacerbation. Methods We retrospectively analyzed 148 patients with chronic obstructive pulmonary disease who were admitted to our hospital between December 2015 and December 2017. The patients were divided into low eosinophil levels according to eosinophils levels.Group(Eos≤2%) and high eosinophils level group(Eos>2%), the clinical data and various indicators of the two groups of patients were compared,and the difference in treatment effect and survival condition between the two groups was compared. Results Patients in the high eosinophil level group had shorter hospital stay and lower mortality than those in the low eosinophil group(P<0.05); high eosinophil level patients total The effective rate was 93.94%, and the total effective rate was 78.05% in patients with low eosinophils level, the difference was statistically significant(P<0.05); the incidence of complications in high eosinophils group was 12.12%, low The incidence of complications in the eosinophils group was21.96%, and the difference was statistically significant(P<0.05). Conclusion Patients with chronic exacerbation of chronic obstructive pulmonary disease at high eosinophil levels have a better response to hormone therapy, can shorten hospital stay, reduce the incidence of patient complications and mortality, and improve the survival of patients.
Objective To investigate the effect of eosinophils on the treatment and survival of patients with chronic obstructive pulmonary disease during acute exacerbation. Methods We retrospectively analyzed 148 patients with chronic obstructive pulmonary disease who were admitted to our hospital between December 2015 and December 2017. The patients were divided into low eosinophil levels according to eosinophils levels.Group(Eos≤2%) and high eosinophils level group(Eos>2%), the clinical data and various indicators of the two groups of patients were compared,and the difference in treatment effect and survival condition between the two groups was compared. Results Patients in the high eosinophil level group had shorter hospital stay and lower mortality than those in the low eosinophil group(P<0.05); high eosinophil level patients total The effective rate was 93.94%, and the total effective rate was 78.05% in patients with low eosinophils level, the difference was statistically significant(P<0.05); the incidence of complications in high eosinophils group was 12.12%, low The incidence of complications in the eosinophils group was21.96%, and the difference was statistically significant(P<0.05). Conclusion Patients with chronic exacerbation of chronic obstructive pulmonary disease at high eosinophil levels have a better response to hormone therapy, can shorten hospital stay, reduce the incidence of patient complications and mortality, and improve the survival of patients.
引文
[1]黎艳聪,张杰斯,郭超文,等.血清淀粉样蛋白A在慢性阻塞性肺疾病急性加重期中的应用价值[J].实用医学杂志,2017,33(14):2349-2352.
[2]慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组.慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2014年修订版)[J].国际呼吸杂志,2014,34(1):1-11.
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264.
[4]王胜,叶海勇,陈悦,等.302例慢性阻塞性肺疾病急性加重期中医证候分型[J].北京中医药大学学报,2015,38(1):57-62.
[5] Vlahos R, Bozinovski S. Recent advances in pre-clinical mouse models of COPD[J]. Clinical Science,2014,126(3/4):253-265.
[6]罗炜,杨超培,王慧等.诱导痰MUC5AC在嗜酸粒细胞性支气管炎和支气管哮喘患者中的差异分析[J].重庆医学,2016,45(11):1560-1562.
[7]高莹,谢家政.血嗜酸粒细胞作为糖皮质激素治疗慢性阻塞性肺疾病疗效的生物标志物研究[J].国际呼吸杂志,2016,36(12):948-951.
[8]金晓晴,陈波,王颖,等.外周血嗜酸粒细胞对重症慢阻肺急性加重期患者疗效及预后评价的研究[J].武汉大学学报(医学版),2017,38(3):475-478.
[9]吴胜,饶平,吴清松,等.两种糖皮质激素给药方案治疗老年AECOPD患者的临床观察[J].中国药房,2017,28(14):1972-1975.
[10]吴亮亮,颜春松.慢性阻塞性肺疾病并发症研究进展[J].中国老年学杂志,2016,36(16):4127-4130.
[2]慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组.慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2014年修订版)[J].国际呼吸杂志,2014,34(1):1-11.
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264.
[4]王胜,叶海勇,陈悦,等.302例慢性阻塞性肺疾病急性加重期中医证候分型[J].北京中医药大学学报,2015,38(1):57-62.
[5] Vlahos R, Bozinovski S. Recent advances in pre-clinical mouse models of COPD[J]. Clinical Science,2014,126(3/4):253-265.
[6]罗炜,杨超培,王慧等.诱导痰MUC5AC在嗜酸粒细胞性支气管炎和支气管哮喘患者中的差异分析[J].重庆医学,2016,45(11):1560-1562.
[7]高莹,谢家政.血嗜酸粒细胞作为糖皮质激素治疗慢性阻塞性肺疾病疗效的生物标志物研究[J].国际呼吸杂志,2016,36(12):948-951.
[8]金晓晴,陈波,王颖,等.外周血嗜酸粒细胞对重症慢阻肺急性加重期患者疗效及预后评价的研究[J].武汉大学学报(医学版),2017,38(3):475-478.
[9]吴胜,饶平,吴清松,等.两种糖皮质激素给药方案治疗老年AECOPD患者的临床观察[J].中国药房,2017,28(14):1972-1975.
[10]吴亮亮,颜春松.慢性阻塞性肺疾病并发症研究进展[J].中国老年学杂志,2016,36(16):4127-4130.